- Policy
- Cases for Pre-approval of Ultomiris exceeds 100
- by Lee, Tak-Sun Jun 9, 2022 06:25am
- The number of approved Ultomiris administered was 101 until April. Ultomiris, a treatment for paroxysmal nocturnal hemoglobinuria (PNH), has been shown to have completely replaced Soliris, the existing treatment since its benefits in June last year. Both are expensive rare drugs, and must be approved in advance by the Board of Review
- Policy
- Monkeypox becomes Class 2 infectious disease in Korea
- by Lee, Jeong-Hwan Jun 9, 2022 06:24am
- The viral zoonosis monkeypox will be designated and managed as a ‘Class 2 infectious disease’ by law starting today (8th). With its level raised, monkeypox will now be managed and considered to have the same level of risk as COVID-19, tuberculosis, and chickenpox. If a person is confirmed with a Class 2 infectious disease, this mus
- Policy
- Evusheld is expected to be introduced this month
- by Lee, Jeong-Hwan Jun 9, 2022 06:24am
- The government is expected to introduce Evusheld, a COVID-19 antibody treatment that is administered to patients who do not form antibodies well even with vaccinations, to Korea this month. Lee Ki-il, the first general coordinator of the Central Disaster and Safety Countermeasures Headquarters, presided over a meeting at the Sejong Governm
- Policy
- Bringing 3rd gen monkeypox vaccine to Korea in discussion
- by Lee, Jeong-Hwan Jun 8, 2022 05:56am
- The government announced on the 7th that it has started discussions on the quantity and schedule for bringing a ‘3rd generation monkeypod vaccine’ to Korea with its manufacturer. The authorities decided to accelerate the introduction of this third-generation vaccine with proven efficacy as the number of confirmed cases of monkeypox cont
- Policy
- The price gap between Memantine products is more than 2.5x
- by Lee, Tak-Sun Jun 7, 2022 06:04am
- The price difference between Memantine producst was more than 2.5 times. This is because if there are more than 20 generics depending on the price calculation formula, new products are listed at 85% of the lowest price. Memantine preparations have originally had a large price gap between products, but the gap is widening according to this pri
- Policy
- Price Negotiation for One-shot Treatment Zolgensma
- by Lee, Tak-Sun Jun 7, 2022 06:04am
- Zolgensma of Novartis, which passed the Drug Reimbursment Evaluation Committee of the HIRA on the 12th of last month, began negotiations on drug prices to register health insurance benefits. Given that Kymriah of the same company, which has attracted attention as a once-in-a-lifetime drug, succeeded in being reimbursed two months after passin
- Policy
- Zerbaxa passed evaluation committee after 4 yrs of challenge
- by Lee, Tak-Sun Jun 3, 2022 06:36am
- MSD Korea's antibiotic drug Zerbaxa has been recognized for its benefit adequacy by the HIRA Drug Reimbursment Evaluation Committee. As a result, it is likely to be listed on health insurance benefits through NHIS negotiations. The HIRA released the results of the 6th Drug Reimbursment Evaluation Committee review on the 2nd, and determined
- Policy
- Lioresal was newly listed
- by Kim, Jung-Ju Jun 2, 2022 05:59am
- With the new registration of 10mg/5mL of the skeletal muscle relaxant, the standard was newly established this month. Jakabi 5mg, which belongs to an anti-malignant tumor drug, has been clearly set in accordance with the change in permission from the MFDS. The MOHW announced that it partially revised the "details on the criteria and method
- Policy
- New guidelines for Lagevrio & Paxlovid have been released
- by Kim, Jung-Ju Jun 2, 2022 05:58am
- New clinical guidelines for Lagevrio and Paxlovid's administration of COVID-19 patients have been released. Lagevrio considers medication if it is difficult to use other treatments among confirmed patients with mild and severe symptoms over the age of 18, and Paxlovid considers patients aged 12 or older who weigh more than 40kg. Eight m
- Policy
- The GMP reinforcement bill passed the plenary session
- by Lee, Jeong-Hwan Jun 2, 2022 05:58am
- Sustainable Support for New Drug Development Pharmaceutical Companies Increasing Punishment for Violations of GMP A bill to extend special cases for innovative pharmaceutical companies and a bill to significantly strengthen the level of GMP regulatory management compared to the previous one passed the plenary session of the National Assemb
